$NOK

Here are Tuesday's biggest analyst calls: Nvidia, Apple, AMD, Etsy, Eli Lilly, Samsara & more

Analysts made several calls on Tuesday, including upgrades for Nokia (NOK), The New York Times (NYT), Agilon (AGL), and Eli Lilly (LLY). Price targets were raised for NYT ($82), AGL ($125), and Palantir (PLTR, $250). Other notable actions include initiations on Janus Living, Vishay Intertechnology (VSH), and Samsara (IOT).

Original reporting
Published Sep 15, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 2:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here are Tuesday's biggest analyst calls: Nvidia, Apple, AMD, Etsy, Eli Lilly, Samsara & more — source image
Decision brief

The 30-second read

$NOKBullishMed
01

Why it matters

The collective upgrades provide short‑term buying opportunities but lack deep fundamental catalysts, suggesting limited durability.

02

Market read

Analyst sentiment broadly positive, especially for AI‑related and tech stocks, potentially supporting market breadth.

03

What to watch

Many upgrades lack underlying earnings data; price targets may be optimistic.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst houses released a series of upgrades, initiations, and target revisions across multiple sectors.

Company-level read

Ticker impact

$NOKBullishMedium confidence
Context

Rosenblatt initiates Nokia as buy, citing AI infrastructure positioning.

Expected impact

Modest upside as investors absorb upgrade.

Evidence & confidence

Buy initiation with target suggests ~20% upside.

$NYTBullishMedium confidence
Context

Guggenheim upgrades The New York Times Company to buy with new price target.

Expected impact

Short‑term rally expected.

Evidence & confidence

Buy rating and 20% upside target provide clear catalyst.

$AGLBullishMedium confidence
Context

Bernstein upgrades Agilon Health to outperform, raising target to $125.

Expected impact

Potential modest upside.

Evidence & confidence

Target increase reflects better outlook.

$VSHBullishMedium confidence
Context

Oppenheimer initiates Vishay Intertechnology as outperform with $42 PT.

Expected impact

Potential short‑term rally.

Evidence & confidence

Initiation and PT imply upside.

$NOCBullishMedium confidence
Context

Guggenheim initiates Northrop Grumman as buy, citing unique capabilities.

Expected impact

Modest upside.

Evidence & confidence

Defense sector upgrade often supportive.

$BSYBullishMedium confidence
Context

Cantor Fitzgerald initiates Bentley Systems as overweight.

Expected impact

Potential rally.

Evidence & confidence

Weight increase signals confidence.

$ULTANeutralLow confidence
Context

Wells Fargo upgrades Ulta to equal weight from underweight.

Expected impact

Limited impact.

Evidence & confidence

Equal weight is a modest change.

$IOTBullishMedium confidence
Context

Cantor Fitzgerald initiates Samsara as overweight, highlighting IoT moat.

Expected impact

Potential upside.

Evidence & confidence

Strong thesis on market position.

Market effects

Broad analyst upgrades lift tech, healthcare, and industrial sectors.

US equity sentiment reinforced, especially AI‑related names.

Limited to US‑listed companies; no direct global macro effect.

Counterpoint

Upgrades may be premature if earnings miss expectations later.

Key entities

  • Rosenblatt

    Initiated Nokia as buy.

  • Guggenheim

    Upgraded NYT and initiated NOC.

  • Bank of America

    Reiterated buy on NVDA, MRVL, AMD.

Related articles

$ETSYMedAI 8/10

ETSY INC (ETSY): Third Quarter 2026

ETSY INC (ETSY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Third Quarter 2026 Shareholder Letter Nicky, ‘WinkingCatClay’ shop on Etsy 2 D ear Shareholders, 2026 has been a year of meaningful transformation for Etsy. We entered the year with a clear diagnosis of the business’ needs and a set of priorities designed to address them. At the

$LLYMed

Lilly’s retatrutide shows greater efficacy than Ozempic in trial

Eli Lilly (NYSE:LLY) reported that retatrutide outperformed Ozempic in a Phase 3 trial for type 2 diabetes. Retatrutide reduced A1C levels by 2.2% vs. Ozempic's 1.8% and led to 44-47 lbs weight loss vs. Ozempic's 21 lbs. Both doses met primary and secondary endpoints. Common side effects included diarrhea and nausea. Retatrutide is not yet FDA-approved.

$LLYMedAI 8/10

Ozempic led to less weight loss and blood-sugar reduction than Lilly's drug in a diabetes trial.

Eli Lilly's retatrutide showed greater A1C reduction and more than double the weight loss compared to Novo Nordisk's Ozempic in a Phase 3 trial for type 2 diabetes. Participants lost 44-47 lbs on average. Lilly's Kenneth Custer highlighted the potential to shift treatment paradigms. Detailed results will be presented later. Retatrutide is not yet approved.